DALLAS, Texas 8/30/2008 2:30:18 AM
News / Business

Beacon Equity Issues Technical Trade Alerts on: CEGE, AMLN, DNA, GENZ, AMGN, GILD

DALLAS, Texas - Today’s Trade Alerts include: Cell Genesys Inc. (Nasdaq: CEGE), Amylin Pharmaceuticals Inc. (Nasdaq: AMLN), Genentech Inc. (NYSE: DNA), Genzyme Corp. (Nasdaq: GENZ), Amgen Inc. (Nasdaq: AMGN) and Gilead Sciences Inc. (Nasdaq: GILD).

After a nearly 30% hike yesterday, Cell Genesys Inc. (CEGE) shares climbed nearly 1% Friday morning, trading at $1.03.  Cell Genesys, a biotechnology company, engages in the development and commercialization of biological therapies for patients with cancer.  It develops cell-based cancer immunotherapies and oncolytic virus therapies...

Cell Genesys shares recently bounced back after dropping 72% to an all-time low Wednesday when the company stopped a clinical trial of its prostate cancer vaccine GVAX.  The company stopped VITAL-2, one of two late-stage tests of GVAX, because more incidents of death were found with patients who received GVAX than those who received only a standard treatment

However, according to Canaccord Adams analyst Joseph Pantginis, earlier clinical trials and the on-going VITAL-1 tests, which included healthier patients, demonstrated the vaccine to be clearly effective and found to prolong survival...”

Amylin Pharmaceuticals Inc. (AMLN) shares rose 1.23% to $22.15 Friday morning. Amylin Pharmaceuticals, a biopharmaceutical company, engages in the discovery, development and commercialization of medicines for diabetes, obesity and other diseases in the United States…

Shares of Amylin Pharmaceuticals now slightly recover after a sharp decline of the stock on news by the company and its partner Eli Lilly & Co. of new deaths among patients taking their diabetes treatment Byetta.  Both companies in a conference call recently provided context and additional information regarding the August 18, 2008, U.S. Food and Drug Administration (FDA) update to a prior alert for BYETTA (exenatide) injection referencing pancreatitis

Wall Street is also concerned about how the reported deaths might affect prescription growth, along with any impact from stricter warnings on Byetta's label…”

Investors can view all of the TraderNotes and investment articles for free by visiting:
http://www.beaconequity.com/m

Join the fastest growing investor community at:
http://www.stocknetworkonline.com/

BeaconEquity.com’s Market News is one of the fastest growing small cap blogs in the investment community. Beacon is the authority on research in the small cap sector, and our analysts strive each day to find the stocks that are poised to be the biggest movers before the rest of the market is aware of them.

We encourage investors to subscribe to our FREE newsletter filled with daily trading ideas by visiting: http://www.BeaconEquity.com/m

BeaconEquity.com is one of the industry’s largest small cap research providers. Beacon strives to provide a balanced view of many promising small cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the publicly available information available on them. For more information on Beacon Research, please visit: http://www.BeaconEquity.com

Beacon Equity Research Disclosure

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT OR WEB SITE. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority.  We are neither licensed nor qualified to provide investment advice.

The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice.  The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities.  We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

Our newsletter and Web site have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company.  An individual should never invest in the securities of any of the companies profiled based solely on information contained in our report.  Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.

Any individual who chooses to invest in any securities should do so with caution.  Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested.  Always research your own investments and consult with a registered investment advisor or licensed stock broker before investing.

BeaconEquity.com is a Web site wholly owned by BlueWave Advisors, LLC. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. BlueWave Advisors LLC, its principal and/or its affiliates will hold positions in the company profiled and may buy or sell securities at any time without notice.

Information contained in our report will contain “forward looking statements” as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934.  Subscribers are cautioned not to place undue reliance upon these forward looking statements. These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company's most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements.

We are committed to providing factual information on the companies that are profiled.  However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company's plans or ability to effect any planned or proposed actions.  We have no first-hand knowledge of any profiled company’s operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so.  Statistical information, dollar amounts, and market size data was provided by the subject company and related sources which we believe to be reliable.

To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information).

We encourage you to invest carefully and read investment information available at the Web sites of the SEC at http://www.sec.gov and FINRA at http://www.finra.org

Source: BeaconEquity.com

Beacon Equity Research
Jeff Bishop, (469)-252-3505
press@beaconequity.com